Efficacy and Safety of Transvenous Lead Extraction at the Time of Upgrade from Pacemakers to Cardioverter-Defibrillators and Cardiac Resynchronization Therapy

被引:1
|
作者
Stefanczyk, Pawel [1 ]
Nowosielecka, Dorota [1 ,2 ]
Polewczyk, Anna [3 ,4 ]
Jachec, Wojciech [5 ]
Glowniak, Andrzej [6 ]
Kosior, Jaroslaw [7 ]
Kutarski, Andrzej [6 ]
机构
[1] Pope John Paul II Prov Hosp, Dept Cardiol, PL-22400 Zamosc, Poland
[2] Pope John Paul II Prov Hosp, Dept Cardiac Surg, PL-22400 Zamosc, Poland
[3] Jan Kochanowski Univ, Inst Med Sci, Dept Physiol Pathophysiol & Clin Immunol, PL-25369 Kielce, Poland
[4] Swietokrzyskie Cardiol Ctr, Dept Cardiac Surg, PL-25736 Kielce, Poland
[5] Silesian Med Univ Katowice, Fac Med Sci Zabrze, Dept Cardiol 2, PL-41800 Zabrze, Poland
[6] Med Univ, Dept Cardiol, PL-20059 Lublin, Poland
[7] Masovian Specialist Hosp, Dept Cardiol, PL-26617 Radom, Poland
关键词
device upgrade; transvenous lead extraction; prophylaxis of lead abandonment; restoration of venous access; EXPERT CONSENSUS STATEMENT; VENOUS OCCLUSION; DEVICE UPGRADE; IMPLANTATION;
D O I
10.3390/ijerph20010291
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Upgrading from pacemakers to ICDs and CRTs is a difficult procedure, and often, transvenous lead extraction (TLE) is necessary for venous access. TLE is considered riskier in patients with multiple diseases. We aimed to assess the complexity, risk, and outcome of TLE among CRT and ICD candidates. Methods: We analyzed clinical data from 2408 patients undergoing TLE between 2006 and 2021. There were 138 patients upgraded to CRT-D, 33 patients upgraded to CRT-P and 89 individuals upgraded to ICD versus 2148 patients undergoing TLE for other non-infectious indications. Results: The need for an upgrade was the leading indication for TLE in only 36-66% of patients. In 42.0-57.6% of patients, the upgrade procedure could be successfully done only after reestablishing access to the occluded vein. All leads were extracted in 68.1-76.4% of patients, functional leads were retained in 20.2-31.9%, non-functional leads were left in place in 0.0-1.1%, and non-functional superfluous leads were extracted in 3.6-8.4%. The long-term survival rate of patients in the CRT-upgrade group was lower (63.8%) than in the non-upgrade group (75.2%). Conclusions: Upgrading a patient from an existing pacemaker to an ICD/CRT is feasible in 100% of cases, provided that TLE is performed for venous access. Major complications of TLE at the time of device upgrade are rare and, if present do not result in death.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Transvenous lead performance of implantable cardioverter-defibrillators and pacemakers
    Mori, Hitoshi
    Kato, Ritsushi
    Ikeda, Yoshifumi
    Tsutsui, Kenta
    Hoya, Hiroki
    Tanaka, Sayaka
    Iwanaga, Shiro
    Nakano, Shintaro
    Muramatsu, Toshihiro
    Sumitomo, Naokata
    Matsumoto, Kazuo
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2021, 44 (03): : 481 - 489
  • [2] Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Women
    Ignaszewski, Maya T.
    Daugherty, Stacie L.
    Russo, Andrea M.
    HEART FAILURE CLINICS, 2019, 15 (01) : 109 - +
  • [3] Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators
    Ermis, C
    Seutter, R
    Zhu, AX
    Benditt, LC
    VanHeel, L
    Sakaguchi, S
    Lurie, KG
    Lu, F
    Benditt, DG
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (12) : 2258 - 2263
  • [4] Unmet needs for implantable cardioverter-defibrillators and cardiac resynchronization therapy
    Stavtseva, YVYuliya
    Villevalde, S. V.
    Kobalava, Z. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 155 - 155
  • [5] Efficacy and safety of cardiac rehabilitation in patients with implantable cardioverter defibrillators and cardiac resynchronization therapy
    Brochado, B.
    Santos, M.
    Anjo, D.
    Rodrigues, P.
    Sousa, M. J.
    Viamonte, S.
    Fernandes, J. P.
    Carvalho, H.
    Gomes, L.
    Torres, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S150 - S151
  • [6] Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
    Chan, Yin
    Pranke, Stephanie
    Rashidi, Farid
    Nosib, Shravan
    Worobetz, Lawrence
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 2017
  • [7] Safety Profile of Liver FibroScan® in Patients With Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
    Chan, Yin
    Pranke, Stephanie
    Wang, Samuel
    Nosib, Shravan
    Worobetz, Lawrence
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S892 - S892
  • [8] Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Older Adults With Heart Failure
    Sandhu, Amneet
    Levy, Andrew
    Varosy, Paul D.
    Matlock, Daniel
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 (10) : 2193 - 2199
  • [9] Advances in remote monitoring of implantable pacemakers, cardioverter defibrillators and cardiac resynchronization therapy systems
    Werner Jung
    Andreas Rillig
    Ralf Birkemeyer
    Tomislav Miljak
    Udo Meyerfeldt
    Journal of Interventional Cardiac Electrophysiology, 2008, 23 : 73 - 85
  • [10] Transvenous lead extraction of implantable cardioverter-defibrillators: A comprehensive outcome-and risk factor analysis
    Chung, Da-Un
    Burger, Heiko
    Kaiser, Lukas
    Osswald, Brigitte
    Baersch, Volker
    Naegele, Herbert
    Knaut, Michael
    Reichenspurner, Hermann
    Gessler, Nele
    Willems, Stephan
    Butter, Christian
    Pecha, Simon
    Hakmi, Samer
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2023, 46 (08): : 815 - 823